Brind.

TD Cowen analysts questioned Genpact management regarding the company's operations.

1 report, 1 independent Updated Aug 14

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Genpact TD Cowen

Keep exploring

The entities involved

Genpact
New York professional services firm
- Citigroup issued a neutral rating on Genpact shares, while TD Cowen reduced its price target and set a buy rating.Mon 09:06
- Lashovitsky gained professional experience at three major firms: Genpact, Booz Allen Hamilton, and UBS.Wed 12:31
TD Cowen
American investment bank
- Analyst downgraded Ag Growth International Inc. due to debt management risks.Mon 12:33
- TD Cowen raised its price target and gave a buy rating for Travere Therapeutics, Inc., while various institutional investors bought into the company.Mon 10:36

Coverage

Newest first; wire copies grouped

Aug 14StockStory5 Must-Read Analyst Questions From Genpact’s Q2 Earnings Call Genpact delivered a positive second quarter, with results surpassing Wall Street’s revenue and non-GAAP profit expectations. Management a